TOPLINE A phase 3 trial found that replacing two cycles of intensive chemotherapy with two cycles of blinatumomab significantly improved event-free survival (EFS) among children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL). The estimated 4-year EFS rates were 83.0% among patients who received blinatumomab and 70.3% among those who continued receiving additional chemotherapy …
Read More
Blinatumomab Boosts EFS in Children With High-Risk B-ALL
